Get the Stockscreener App
2.17
10.70%
-0.26
After Hours:
2.17
Caribou Biosciences Inc stock is traded at $2.17, with a volume of 5.10M.
It is down -10.70% in the last 24 hours and down -4.41% over the past month.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
See More
Previous Close:
$2.43
Open:
$2.4
24h Volume:
5.10M
Relative Volume:
2.44
Market Cap:
$202.08M
Revenue:
$34.48M
Net Income/Loss:
$-102.07M
P/E Ratio:
-1.4863
EPS:
-1.46
Net Cash Flow:
$-104.90M
1W Performance:
-12.15%
1M Performance:
-4.41%
6M Performance:
+146.59%
1Y Performance:
-7.26%
1-Day Range:
$2.13
$2.47
1-Week Range:
$2.13
$3.535
52-Week Range:
$0.66
$3.535
Caribou Biosciences Inc Stock (CRBU) Company Profile
Name
Caribou Biosciences Inc
Sector
Industry
Phone
510-982-6030
Address
2929 7TH STREET, SUITE 105, BERKELEY
Compare CRBU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
2.17 | 226.29M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-03-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-08-23 | Initiated | Cantor Fitzgerald | Neutral |
| Oct-31-23 | Initiated | Evercore ISI | Outperform |
| Jul-11-23 | Initiated | Truist | Buy |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-30-21 | Initiated | H.C. Wainwright | Buy |
| Nov-15-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-17-21 | Initiated | BofA Securities | Buy |
| Aug-17-21 | Initiated | Citigroup | Neutral |
| Aug-17-21 | Initiated | SVB Leerink | Outperform |
View All
Caribou Biosciences Inc Stock (CRBU) Latest News
Traders Purchase Large Volume of Caribou Biosciences Call Options (NASDAQ:CRBU) - MarketBeat
Caribou Biosciences (NASDAQ:CRBU) Given New $8.00 Price Target at Citigroup - MarketBeat
Truist Securities reiterates Buy rating on Caribou Biosciences stock By Investing.com - Investing.com Nigeria
Published on: 2025-11-04 03:55:22 - newser.com
How to build a custom watchlist for Caribou Biosciences Inc.Bear Alert & AI Powered Buy/Sell Recommendations - newser.com
Statistical indicators supporting Caribou Biosciences Inc.’s strengthMarket Performance Summary & Risk Managed Trade Strategies - newser.com
Analyzing Caribou Biosciences Inc. with multi timeframe chartsWatch List & Reliable Price Breakout Alerts - newser.com
Comparing Caribou Biosciences Inc. in custom built stock radarsQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
What machine learning models say about Caribou Biosciences Inc.Earnings Risk Report & Community Verified Swing Trade Signals - newser.com
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - Investing News Network
Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma - Investing News Network
Is Caribou Biosciences Inc. stock a contrarian buy2025 Winners & Losers & Safe Swing Trade Setup Alerts - newser.com
Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - Stocktwits
Caribou Biosciences to Participate in Upcoming Investor Conferences - The Manila Times
Caribou Biosciences Stock Rises 3% After Dual Positive Phase 1 Trial Updates - Nasdaq
Caribou Biosciences: A Much Anticipated Data Readout Does Not Quite Get My Buy - Seeking Alpha
Why Is CRISPR Genome-Editing Firm Caribou Biosciences Stock Trading Higher Today> - Benzinga
Caribou Bio leaps on early data for vispa-cel - The Pharma Letter
CRBU: Citigroup Analyst Raises Price Target for Caribou Bioscien - GuruFocus
Alert inadvertently tagged to Caribou Biosciences withdrawn - MarketScreener
Caribou Biosciences Shares Double After Strong Multiple Myeloma Trial Results - MSN
Ranking Caribou Biosciences Inc. among high performing stocks via toolsPortfolio Risk Summary & Verified Short-Term Trading Plans - newser.com
Is it time to cut losses on Caribou Biosciences Inc.Weekly Investment Recap & Smart Swing Trading Alerts - newser.com
Caribou Says Potential Non-Hodgkin Lymphoma Therapy Shows High Overall Response; Shares Rise Pre-Bell - MarketScreener
Will Caribou Biosciences Inc. stock go up soonMarket Activity Report & Fast Moving Trade Plans - newser.com
Caribou Biosciences expects cash and marketable securities as of Sept 30 to be $159.2 million - MarketScreener
Caribou Biosciences Reports Positive ANTLER Phase 1 Results - TipRanks
Using flow based indicators on Caribou Biosciences Inc.July 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Caribou Biosciences announces results from CaMMouflage Phase 1 trial - TipRanks
Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies - The Manila Times
Caribou Biosciences stock soars after positive multiple myeloma therapy data By Investing.com - Investing.com UK
Why Caribou Biosciences Inc. stock remains on buy lists2025 Key Lessons & Free Accurate Trade Setup Notifications - newser.com
Caribou Biosciences Soars Over 120%What's Driving The Rally? - Nasdaq
Caribou’s off-the-shelf CAR-T therapy shows promise in lymphoma study - statnews.com
Caribou Biosciences (NASDAQ: CRBU): 91% MRD negativity; CB-011 dose expansion planned - Stock Titan
Using Bollinger Bands to evaluate Caribou Biosciences Inc.2025 Historical Comparison & Free Expert Approved Momentum Trade Ideas - newser.com
Published on: 2025-11-03 00:52:40 - newser.com
Risk adjusted return profile for Caribou Biosciences Inc. analyzedSwing Trade & High Conviction Investment Ideas - newser.com
Caribou Biosciences to Host Webcast Reporting New Clinical Data for Anti-CD19 and Anti-BCMA CAR-T Cell Therapies - Quiver Quantitative
Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma - The Manila Times
Caribou Biosciences Inc Stock (CRBU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):